Bridges Investment Management Inc. Acquires Shares of 2,934 DexCom, Inc. $DXCM

Bridges Investment Management Inc. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent filing with the SEC. The fund bought 2,934 shares of the medical device company’s stock, valued at approximately $256,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Golden State Wealth Management LLC raised its position in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after acquiring an additional 264 shares during the period. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom during the 1st quarter worth approximately $27,000. Anderson Financial Strategies LLC bought a new stake in shares of DexCom in the 1st quarter worth approximately $37,000. Alpine Bank Wealth Management purchased a new position in DexCom in the first quarter valued at approximately $40,000. Finally, Private Trust Co. NA lifted its position in shares of DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after buying an additional 335 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Barclays upped their price target on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 30th. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. The Goldman Sachs Group cut their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $106.00 price target on shares of DexCom in a report on Monday, September 29th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $97.00.

DexCom Price Performance

DXCM stock opened at $66.60 on Friday. The firm has a 50 day simple moving average of $73.35 and a two-hundred day simple moving average of $77.52. The stock has a market cap of $26.12 billion, a PE ratio of 46.25, a P/E/G ratio of 1.39 and a beta of 1.47. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter last year, the company posted $0.43 EPS. The business’s quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the transaction, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. This represents a 1.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the transaction, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.